5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 13,146 as of Friday, Dec. 14, 2012, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,344 issues advancing vs. 1,517 declining with 152 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Centene Corporation ( CNC), down 8.5%, WellCare Health Plans ( WCG), down 5.9%, Molina Healthcare ( MOH), down 4.3% and Life Technologies ( LIFE), down 1.4%. Top gainers within the industry include Community Health Systems ( CYH), up 1.6%, ResMed ( RMD), up 1.0% and Quest Diagnostics ( DGX), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Thermo Fisher Scientific ( TMO) is one of the companies pushing the Health Services industry lower today. As of noon trading, Thermo Fisher Scientific is down $0.38 (-0.6%) to $64.54 on average volume Thus far, 879,801 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $64.49-$64.85 after having opened the day at $64.80 as compared to the previous trading day's close of $64.92.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $23.5 billion and is part of the health care sector. The company has a P/E ratio of 20.8, above the S&P 500 P/E ratio of 17.7. Shares are up 44.9% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Thermo Fisher Scientific Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Jim Cramer: Agilent Technology Has Been One of My Favorites

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Cramer: Secondary Offerings Get Primary Attention

The Stock Market Is on Fire, Especially in These Sectors: Market Recon

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria